Clinical Trial Update: A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating the efficacy and safety of efgartigimod in patients with Primary Sjögren's syndrome. The study is sponsored by argenx and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjögren Syndrome

Drugs mentioned

• VYVGART (EFGARTIGIMOD ALFA)

Snippet

Sponsor: argenx | Conditions: Primary Sjogrens Disease | Phase 3 | Status: ACTIVE_NOT_RECRUITING